Obesity, insulin resistance, and diabetes are related disorders of energy metabolism for which therapies are suboptimal. In this issue of Cell, Lee et al. (2007) demonstrate in mice that bone regulates the insulin/glucose axis and energy metabolism, providing a new framework for approaching common disorders of bioenergetics.
standing of how proteins such as AcbA are secreted. Several different pathways can mediate the unconventional secretion of cytosolic proteins (Nickel, 2005) . One such pathway is direct translocation across the plasma membrane via ATP-driven ABC transporters, but data from Kinseth et al. (2007) argue against this route for AcbA. An alternative possibility is depicted in Figure 1 . In this scenario, AcbA is transported from the cytosol into the internal vesicles of endosomal multivesicular bodies (MVBs), which subsequently fuse with the plasma membrane to release the internal vesicles as exosomes. GrpA would be needed at some stage of this process. Support for such a mechanism comes from the finding that AcbA can be visualized in association with an endosomal compartment underneath the plasma membrane (Adam Kuspa, personal communication).
If we assume that GrpA is required for MVBs to fuse with the plasma membrane, two models could explain this requirement. In the first model ( Figure 1A ), GrpA shuttles between the Golgi and the plasma membrane and has distinct functions at the two locations. At the plasma membrane, GrpA would operate as part of the MVB fusion machinery. This idea raises the exciting possibility that GRASPs act as a go-between to coordinate the activities of the conventional and unconventional secretory pathways. In the second model ( Figure 1B ), GrpA operates exclusively at the Golgi and is selectively required for the biosynthetic transport of a plasma membrane component of the MVB fusion machinery. Hence, further insight into Dictyostelium sporulation may illuminate the role of GRASPs in protein transport. Of course, variations on these models can be envisioned. For example, GrpA function might be required at the step of AcbA internalization into MVBs or for an unconventional secretory pathway that is independent of MVBs. Regardless, the elegant work of Kinseth et al. (2007) has revealed a surprising link between conventional and unconventional secretion. Obesity is becoming so prevalent in Western populations that it may already be adversely affecting mortality rates (Adams et al., 2006) . It is a disorder of energy metabolism that predisposes to diabetes, hypertension, and hyperlipidemia, diseases characterized by insulin resistance and complicated by atherosclerosis (Semenkovich, 2006) . Availability of nutrient-dense food and the acceptance of exercise as optional may explain why adiposity is increasing in populations. Yet, there is a limited understanding of the striking differences between individuals in metabolic rate and susceptibility to obesity-associated disease. Once obesity is established, therapies are seldom successful. Treatment is focused on manifestations such as elevated blood sugar, blood pressure, and cholesterol, instead of the underlying disorder of energy metabolism. In this issue, Lee and colleagues (2007) make the surprising observation that bone, a tissue not previously thought to impact bioenergetics, can affect adiposity, glucose metabolism, and insulin sensitivity. People with obesity and diabetes are known to have abnormalities of bone metabolism. Increased adiposity is a risk factor for fracture in children (Goulding et al., 2001) , and diabetics are prone to fracture, although there is little evidence that they are predisposed to osteoporosis (Schwartz et al., 2001 ). However, the rate of bone turnover is decreased in diabetics as reflected by diminished expression of biomarkers of bone resorption and formation, including osteocalcin, an osteoblastspecific protein (Gerdhem et al., 2005) . Common thinking holds that the decrease in osteoblast activity (the cells that build bone) results from the consequences of diabetes including hyperglycemia, and decreased levels or effectiveness of insulin and IGF-1 (Inaba, 2004) . Lee et al. (2007) now present data to challenge this notion and raise the provocative concept that the reduction in osteoblast function may contribute to obesity and glucose intolerance. In this scenario, a vicious cycle would exist in which the metabolic sequelae of diabetes suppress osteoblast function, leading to diminished osteocalcin bioactivity, which in turn further aggravates obesity and insulin resistance.
Bone Weighs in on Obesity
Several lines of evidence from Lee and colleagues support the notion that osteoblasts can alter energy metabolism. Mice with genetic inactivation of Esp, which encodes the osteoblast protein tyrosine phosphatase OST-PTP, have numerous metabolically desirable characteristics: increased proliferation of pancreatic beta cells, increased insulin secretion, lower blood sugar, increased insulin sensitivity, decreased visceral fat, and increased energy expenditure (Figure 1 ). Animals with Esp deficiency are protected from both hyperphagia-induced and dietinduced obesity. Part of their metabolic phenotype may be explained by increased production of adiponectin, a protein secreted from adipocytes that increases fatty acid catabolism. Transgenic mice that overexpress Esp in osteoblasts have decreased pancreatic beta cell proliferation and display hyperglycemia and insulin resistance. Coculture experiments demonstrate that Esp-deficient osteoblasts increase insulin expression in pancreatic islets and increase adiponectin expression in adipocytes, suggesting that Esp controls the bioactivity of a secreted protein that influences pancreatic beta cells as well as adipocytes.
Osteocalcin may be that protein. Osteocalcin-deficient mice are obese with decreased beta cell proliferation, greater insulin resistance, and decreased energy expenditure, the opposite of Esp null mice. Osteocalcin increases insulin and adiponectin expression. In perhaps the most compelling experiment of their paper, Lee et al. (2007) show that Esp null mice that are also heterozygous for osteocalcin deficiency are devoid of the metabolically beneficial characteristics seen in Esp null mice that are wild-type for osteocalcin. This result places the intracellular phosphatase encoded by Esp and the secreted protein osteocalcin in the same pathway linking the skeleton and bioenergetics.
The relationship between Esp and osteocalcin does not appear to involve effects on osteocalcin production or clearance because osteocalcin levels are normal in Esp null mice. Osteocalcin undergoes a posttranslational modification consisting of the γ-carboxylation of glutamic acid residues. Osteocalcin in mice that lack Esp appears to be modified to a lesser extent than it is in wild-type mice. Treatment of osteoblasts with warfarin, an inhibtor of γ-carboxylation, resulted in increased adiponectin expression in coculture experiments using adipocytes, and uncarboxylated (but not carboxylated) osteocalcin increased insulin expression in pancreatic islet cells.
If these observations extend to man, they carry several implications. First, pharmacological inhibition of the Esp gene product could have numerous benefits including the preservation of beta cell function, decreased adiposity, and the advantages of inhibiting a protein with limited tissue distribution. Second, warfarin is commonly used to decrease the risk of thrombosis. Although this therapy is not generally thought to affect energy metabolism, a systematic assessment of glucose metabolism and adiposity in these patients could reveal unexpected effects mediated by osteocalcin. Consistent with this notion, γ-carboxylation of osteocalcin is reportedly decreased in humans with insulin-resistant diabetes (Horiuchi et al., 2004) . Third, the most commonly administered antiosteoporosis drugs, such as bisphosphonates, exert their effect by inhibiting the function of osteoclasts (the cells that resorb bone). Because bone remodeling-an ever-occurring event responsible for skeletal turnover-is characterized by tethering of osteoclast and osteoblast activity, inhibition of bone formation follows osteoclast suppression. In fact, decreased osteocalcin synthesis is a common consequence of bisphosphonate therapy (Greenspan et al., 2005) . Given the The Esp gene, also known as Ptprv, encodes a receptor-like protein phosphatase, OST-PTP. Altering its expression has inverse effects on the metabolic bioactivity of osteocalcin, an osteoblast-specific protein. Increased osteocalcin metabolic bioactivity results in beneficial effects in non-skeletal tissues, including improved pancreatic beta cell function and decreased adiposity.
findings by Lee et al., (2007) , a possible relationship between bisphosphonate therapy, glucose metabolism and adiposity should be explored. Finally, glucocorticoid therapy is common and predisposes patients to both diabetes and osteoporosis. Chronic administration of steroids affects osteoclasts and osteoblasts, suppressing bone formation and thus osteocalcin expression (Kim et al., 2006) . Hence, it is possible that osteoporosis and diabetes, presently considered independent manifestations of glucocorticoid therapy, may be mechanistically linked.
Claude Bernard, the French physiologist, is generally credited with the idea of homeostasis, which involves feedback regulation between distant cell types, the sine qua non of endocrinology. Beta cells and adipocytes were known to talk to bone. Now, we learn that bone is talking back. The details of this conversation could identify new candidates for treating obesity, diabetes, and their complications.
